ACHV vs GFAI vs PTGX vs BCO

For growth investors, The Brink's Company (BCO) is the stronger pick with 5.

0% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). The Brink's Company (BCO) offers the better valuation at 22. 9x trailing P/E (11. 7x forward), making it the more compelling value choice. Analysts rate Achieve Life Sciences, Inc. (ACHV) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, The Brink's Company is actually cheaper at 11.

7x.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to -99. 5% for Guardforce AI Co. , Limited (GFAI). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus ACHV's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 25β versus Guardforce AI Co. , Limited's 2. 31β — meaning GFAI is approximately 822% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 12% for The Brink's Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Brink's Company (BCO) is pulling ahead at 5.

0% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Guardforce AI Co. , Limited grew EPS 88. 3% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Brink's Company (BCO) is the more profitable company, earning 3.

8% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 3. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCO leads at 11. 3% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Brink's Company (BCO) trades at 11.

7x forward P/E versus 30. 6x for Protagonist Therapeutics, Inc. — 18. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACHV: 171. 4% to $13. 00.

In this comparison, BCO (0.

9% yield) pays a dividend. ACHV, GFAI, PTGX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Achieve Life Sciences, Inc. (ACHV) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTGX: +744. 9%, ACHV: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACHV (Healthcare) and GFAI (Industrials) and PTGX (Healthcare) and BCO (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

BCO pays a dividend while ACHV, GFAI, PTGX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.